Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 19/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 19/20 | 0.48 |
| ▸ | PDE4A | P27815 | 18/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 18/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 18/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 18/20 | 0.48 |
| ▸ | PDE5A | O76074 | 17/20 | 0.48 |
| ▸ | PDE1A | P54750 | 15/20 | 0.48 |
| ▸ | PDE1B | Q01064 | 15/20 | 0.48 |
| ▸ | PDE1C | Q14123 | 15/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179696 | 0.85 | MAPT (0.46) | CYP3A4MAPT | |
| SCHEMBL129965 | 0.83 | PDE4A (0.39) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL128940 | 0.82 | MAPT (0.42) | CYP3A4MAPT | |
| SCHEMBL127667 | 0.81 | PDE5A (0.41) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL195535 | 0.76 | MAPT (0.45) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL128994 | 0.71 | PDE4B (0.38) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL16186790 | 0.70 | MAPT (0.31) | CYP3A4MAPT | |
| SCHEMBL127939 | 0.70 | CYP3A4 (0.43) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL14904332 | 0.70 | PDE4A (0.54) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7821022 | 0.70 | MAPT (0.65) | PDE4APDE4BPDE4CPDE4DCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227966-B2 | Antimicrobial agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140315939-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-10-23 | — | — | US | disclosed |
| US-20120059026-A1 | ANTIMICROBIAL AGENTS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059026-A1 | ANTIMICROBIAL AGENTS | ZYX, Q6ZSR9, ZC3HAV1L | PDE3B 1735/4885PDE3A 1963/4885PDE4A 1469/4885 |
| US-20140315939-A1 | ANTIMICROBIAL AGENTS | ZYX, Q6ZSR9, ZC3HAV1L | PDE3B 2124/4885PDE3A 2410/4885PDE4A 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.